Skip to main content

Table 4 Susceptibility patterns for selected antibiotic substances and pathogens per year

From: The epidemiology of bloodstream infections and antimicrobial susceptibility patterns in Thuringia, Germany: a five-year prospective, state-wide surveillance study (AlertsNet)

 

2015

2016

2017

2018

2019

OR (95% CI)

p value

Escherichia coli

Aminopenicillin

941/486

(51.6)

1,282/711

(55.5)

1,426/785

(55.0)

1,595/920

(57.7)

1,536/940

(61.2)

1.06 (1.02; 1.10) 0.006

Fluoroquinolones

941/221

(23.5)

1,286/315

(24.5)

1,441/367

(25.5)

1,600/438

(27.4)

1,567/384

(24.5)

1.01 (0.97; 1.05) 0.72

Cefotaxime

938/100

(10.7)

973/134

(13.8)

912/122

(13.4)

1,228/178

(14.5)

1,355/197

(14.5)

1.08 (1.02; 1.14). 0.007

Carbapenems

941/1

(0.1)

1,286/3

(0.2)

1,441/3

(0.2)

1,600/0

(0.0)

1,538/1

(0.1)

6

Aminoglycosides

941/57

(6.1)

1,286/122

(9.5)

1,473/143

(9.7)

1,594/151

(9.5)

1,535/280

(18.2)2

1.30 (1.21; 1.40) < 0.001

Fosfomycin

339/1

(0.4)

562/6

(1.1)

630/6

(1.0)

637/9

(1.4)

518/7

(1.4)

6

Trimethoprim-sulfamethoxazole

941/293

(31.1)

1281/408

(31.9)

1435/439

(30.6)

1593/444

(27.9)

1533 /403

(26.3)

0.93 (0.89; 0.97) < 0.001

Klebsiella pneumoniae

Fluoroquinolones

181/25

(13.8)

232/38

(16.4)

227/40

(17.6)

254/49

(19.3)

270/36

(13.3)

1.02 (0.91; 1.15) 0.72

Cefotaxime

181/18

(9.9)

197/26

(13.3)

154/21

(13.6)

202/24

(11.9)

242/18

(7.4)

0.93 (0.81; 1.08) 0.35

Carbapenems

181/2

(1.1)

232/0

(0.0)

227/0

(0.0)

254/2

(0.8)

270/2

(0.7)

6

Aminoglycosides

181/7

(3.9)

232/12

(5.2)

227/14

(6.2)

253/18

(7.1)

270/33

(12.2)2

1.47 (1.19; 1.82) < 0.001

Fosfomycin

54/6

(11.1)

117/19

(16.2)

113/15

(13.3)

115/16

(13.9)

92/12

(13.0)

1.01 (0.82; 1.24) 0.95

Trimethoprim-sulfamethoxazole

181/22

(12.2)

231/34

(14.7)

227/33

(14.5)

253/33

(13.0)

270/39

(14.4)

1.06 (0.88; 1.26) 0.56

Pseudomonas aeruginosa

Fluoroquinolones

48/10

(16.3)

72/15

(18.1)

87/23

(16.5)

120/19

(13.5)

5

1.21 (0.97; 1.51) 0.09

Ceftazidime

47/3

(4.8)

72/3

(2.8)

85/7

(7.2)

127/6

(4.0)

5

2.14 (1.29; 3.54) 0.003

Piperacillin/Tazobactam

46/7

(12.2)

71/4

(5.6)

85/9

(9.5)

131/19

(14.1)

5

1.30 (0.97; 1.74) 0.07

Carbapenems

46/4

(9.8)

72/10

(13.9)

88/17

(17.4)

131/17

(11.7)

5

1.17 (0.92; 1.49) 0.20

Aminoglycosides

47/6

(11.9)

72/4

(2.8)

88/8

(7.0)

129/3

(1.6)

5

1.03 (0.72; 1.47) 0.88

Combined resistance3

46/5

(10.9)

71/3

(4.2)

87/8

(9.2)

127/7

(5.5)

5

6

Acinetobacter spp.

    

5

 

Fluoroquinolones

27/5

(18.5)

33/6

(18.2)

35/11

(31.4)

32/8

(25.0)

5

6

Carbapenems

27/0

(0.0)

33/1

(3.0)

35/3

(8.6)

33/1

(3.0)

5

6

Aminoglycosides

27/1

(3.7)

33/0

(0.0)

33/3

(9.1)

32/1

(3.1)

5

6

Combined resistance4

27/0

(0.0)

33/0

(0.0)

33/2

(6.1)

32/1

(3.1)

5

6

  1. Number of tested isolates/number of resistant1 isolates (% resistant). The right column displays the results from the logistic regression with GEE as odds ratio (OR) for resistance for the unadjusted linear predictor year (i.e. OR per year) with 95% confidence interval (95% CI) and corresponding two-sided p-value
  2. 1Resistant and intermediate isolates; number of tested pathogens per year and antimicrobial substance can vary as not always antimicrobial testing for each substance was performed in each isolate, 2increase of resistance most probably due to new EUCAST MIC breakpoints, 3Combined resistance of at least 3 out of 5 antibiotics under surveillance, 4Resistent to all tested antibiotics under surveillance, 5not reported due to change in EUCAST methodology, 6not evaluated due to the small numbers of event